Related Experiment Video
Updated: Feb 28, 2026
Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain
Published on: February 22, 2019
Motivational Interviewing Targeting Pain and Substance Use in Veterans Seeking Service-Connection Payments: A
Marc I Rosen1,2, Kathryn Gilstad-Hayden3,4, Christina M Lazar3,4
1VA Connecticut Healthcare System, West Haven, CT, USA. Marc.Rosen@Yale.edu.
Background:
Veterans filing musculoskeletal disorder (MSD) service claims may also be seeking medical treatment.
Objective:
To determine the effect of Motivational Interviewing to Activate Pain Support (MAPS) on pain and substance use in veterans who recently filed MSD claims.
Participants:
A total of 1101 post 9/11 veterans who had filed MSD compensation claims, were not receiving multimodal pain care from VA and had at least moderately severe pain.
Interventions:
Up to five phone sessions of MAPS compared to treatment-as-usual (TAU).
Main Measures:
Pain severity subscale of the Brief Pain Inventory (BPI) and number of substances above the low-risk threshold of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).
Key Results:
Most (87%) veterans offered MAPS participated, and counselors delivered MAPS with good integrity. At week 36, MAPS participants had significantly greater reductions in pain severity than TAU (-0.78 vs. -0.53; mean difference = -0.25, 95% CI -0.44 to -0.06, p = .011), although rates of clinically meaningful improvement were similar between groups (45.4% MAPS vs. 40.8% TAU; OR = 1.21, 95% CI 0.92-1.59, p = .183). The groups did not differ in self-reported number of pain treatment modalities used (TAU = 3.01 modalities vs. MAPS 3.33 modalities, p = .135); however, MAPS participants had, on average, 54% more outpatient encounters for MSDs than those in TAU (MAPS 7.25 vs. TAU 4.58, p < .001). Substance use did not differ between groups.
Conclusions:
MAPS was associated with more outpatient encounters for MSD and statistically significant reductions in pain severity at week 36; reductions achieving the threshold for clinical significance did not differ by group. Benefits from MAPS, despite pandemic-era disruptions to treatment availability, may have occurred via counselors activating patients to seek MSD treatments, helping them navigate pain care systems, and offering patients support.
Design:
Two-arm, parallel group 36-week multisite randomized pragmatic clinical trial (Clinical Trials.gov: NCT04062214).
Trial Registration:
ClinicalTrials.gov registration (NCT04062214) on August 19, 2019.
Related Concept Videos
01:24Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
01:17Drug Dependence
01:25Analgesia and Pain Management
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...